The facility, called Carrigtohill, is a contrast media fill and finishing manufacturing site.
More than 250 construction roles are expected to be created.
The new facility located on Carrigtohill will enable 25 million more patient doses per year of contrast media by the end of 2027.
Project Details and Commitment
President and chief executive of GE Healthcare’s Pharmaceutical Diagnostics (PDx) segment, Kevin O’Neill, said: "This new facility demonstrates our broader commitment not just to address future demand, but also to increase resiliency and security of industry supply for customers.”
IPS-Integrated Project Services, an engineering firm, will lead the project with construction on the site starting in February 2025.
About Contrast Media and Its Impact
Contrast media are injectable diagnostic imaging agents that help enhance the images of organs and blood vessels during medical imaging.
